Contrasting Innate Pharma (OTCMKTS:IPHYF) and Creative Medical Technology (NASDAQ:CELZ)

Creative Medical Technology (NASDAQ:CELZ) and Innate Pharma (OTCMKTS:IPHYF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares Creative Medical Technology and Innate Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-58.38%	-56.15%
Innate Pharma	N/A	N/A	N/A

Risk and Volatility

Creative Medical Technology has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Creative Medical Technology and Innate Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	0	0	0	0	N/A
Innate Pharma	0	0	0	0	N/A

Earnings & Valuation

This table compares Creative Medical Technology and Innate Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10,000.00	424.78	-$5.29 million	($3.74)	-0.85
Innate Pharma	$66.71 million	2.65	-$8.19 million	N/A	N/A

Creative Medical Technology has higher earnings, but lower revenue than Innate Pharma.

Institutional and Insider Ownership

1.4% of Creative Medical Technology shares are owned by institutional investors. 3.6% of Creative Medical Technology shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.